NEO
NeoGenomics, Inc.
Diagnostics & Research · Healthcare · United States
17.93
close · 2026-10-29
value
35
cheaper than peers35
quality
36
stronger fundamentals36
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 2.76× | 78 |
| price to sales | 3.02× | 63 |
| forward P/E | 52.74× | 18 |
| EV to EBITDA | 103.66× | 9 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 11.2% | 53 |
| debt to equity | 57.1% | 47 |
| operating margin | -4.8% | 42 |
| return on equity | -6.3% | 40 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $43.9M |
| employees | 2,500 |
| first trade | 2004-03-16 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.84 | -0.62 | -0.70 | -1.16 |
| free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M |
| net income | -$108.0M | -$78.7M | -$88.0M | -$144.3M |
| revenue | $727.3M | $660.6M | $591.6M | $509.7M |
| unusual items | -$27.8M | -$6.7M | -$11.1M | -$4.5M |